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Circulating tumor DNA (ctDNA) is cell-free DNA that is released into peripheral blood by
tumor cells. ctDNA harbors somatic mutations and mutant ctDNA obtained from blood can
be used as a biomarker in advanced non-small cell lung cancer (NSCLC). In this study, we
investigated the clinicopathological properties of tumors that shed ctDNA in surgically
resected NSCLC patients.
Methods
Consecutive cases of NSCLC with matching surgically resected tissue specimens and
peripheral or specimen blood samples were eligible for this study. EGFR and KRAS muta-
tions in plasma ctDNA and formalin-fixed paraffin-embedded tissue were analyzed using
peptide nucleic acid clamping-assisted method. The plasma and tissue results were com-
pared according to clinicopathological features.
Results
Mutation analyses were available for 36 cases. EGFR and KRAS mutations were present in
41.7% (15/36) and 16.7% (6/36) of tissue samples, respectively. Among EGFR and KRAS-
mutant tumors, plasma mutation detection sensitivity was 13.3% (2/15) for EGFR and
33.3% (2/6) for KRAS. The presence of ctDNA in plasma was significantly associated with
higher pathological tumor stage (p = 0.028), nodal metastasis (p = 0.016), solid adenocarci-
noma pattern (p = 0.003), tumor necrosis (p = 0.012), larger primary tumor diameter (p =
0.002) or volume (p = 0.002), and frequent mitosis (p = 0.018) in tissue specimens. All
tumors larger than 4 cm in maximal diameter or 25 cm3 in volume shed ctDNA in plasma. In
subgroup analysis among EGFR mutated adenocarcinoma, ctDNA was significantly associ-
ated with nodal metastasis (p = 0.029), vascular invasion (p = 0.029), solid adenocarcinoma
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pattern (p = 0.010), and tumor necrosis (p = 0.010), high mitotic rate (p = 0.009), large patho-
logical tumor size (p = 0.027), and large tumor volume on CT (p = 0.027).
Conclusion
We suggest that primary or total tumor burden, solid adenocarcinoma morphology, tumor
necrosis, and frequent mitosis could predict ctDNA shedding in pulmonary
adenocarcinoma.
Introduction
Identification of oncogenic drivers and development of targeted therapies has changed treat-
ment algorithms for advanced non-small cell lung cancer (NSCLC). Molecular testing for
EGFR, ALK, and ROS1 is currently mandatory for patients with lung cancer in routine prac-
tice [1]. So far, tissue genotyping is considered the gold standard for detecting genetic alter-
ations in tumors. Unfortunately, tumor tissue is not adequate for molecular testing in 20–30%
of NSCLC patients at diagnosis [2, 3]. Moreover, rebiopsy is not always feasible or biopsy tissue
is insufficient to allow molecular testing in NSCLC patients with disease progression on treat-
ment [4]. Plasma contains tumor-derived, extracellular DNA (circulating tumor DNA,
[ctDNA]) and plasma genotyping could be a suitable substitute for mutation analysis when
tumor tissue is unavailable. However, the fraction of ctDNA in the blood is very low and the
sensitivity of plasma genotyping remains a challenge despite continued development of highly
sensitive ctDNA assays [5].
The sensitivity of plasma tests depends on not only preanalytical and analytical factors but
also the rate of ctDNA release from the tumor, so-called “ctDNA shed”. Tumors not shedding
ctDNA most likely have false negative result in plasma, even the tumor have targetable muta-
tion. ctDNA is thought to be released into the plasma when tumor cells are going through
necrosis or apoptosis [6]. ctDNA shedding is related to tumor size, necrosis, and the vascular-
ity of tumor [6, 7]. However, comprehensive histopathological features of shedding tumors in
NSCLC was not evaluated. Most liquid biopsy studies have been performed in advanced
NSCLC. In advanced stages, only a small biopsy specimen is taken, so sampling bias may arise
when evaluating histopathological features of shedding tumors. Herein, we examined the his-
topathology of entire sections of primary lung tumor to assess the histopathological features of
ctDNA shedding tumor.
Several recent studies performed next generation sequencing (NGS) of plasma in surgically
resected lung cancer [8, 9]. Abbosh et al. studied clinicopathological predictors of ctDNA
including clonal/subclonal and driver/passenger mutations [9]. Chen et al. correlated clinico-
pathological factors with ctDNA level in plasma without discriminating mutation type [8].
EGFR and KRAS are the most commonly mutated oncogenes involved in the pathogenesis of
NSCLC. EGFR mutations can predict response to tyrosine kinase inhibitors (TKIs) such as
gefitinib and erlotinib [10], while KRAS mutations are associated with poor response to TKIs
and worse prognosis [11]. Therefore, we focused on detection of EGFR and KRAS mutations
in plasma, which is more clinically relevant.
The objectives of this study were: 1) to compare EGFR and KRAS mutation status between
plasma and tumor tissue in surgically resected TKI-naïve NSCLC; 2) to compare histopatho-
logical features between ctDNA shedding and non-shedding tumors; and 3) to evaluate param-
eters predicting ctDNA shedding.
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Materials and methods
Case selection
Consecutive cases of NSCLC in patients who underwent surgical resection at Gangnam Sever-
ance Hospital (Seoul, South Korea) between May 2016 and October 2017 and had a matching
plasma sample in the biobank were eligible for enrollment in this study. All peripheral blood
samples were obtained within 24 hours just prior to surgery and immediately processed to iso-
late plasma. In cases of lobectomy specimen, pulmonary vessel puncture and blood sampling
was done during frozen sectioning (Fig 1) and plasma was isolated within several hours.
Whole blood was collected in BD VacutainerTM K2 EDTA tubes (BD Bioscience, CA, USA)
and centrifuged for 10 min at 1000 x g and 4˚C temperature with break off setting. Without
disturbing the buffy coat layer or red blood cells, plasma supernatant was aspirated and trans-
ferred to new tubes, then further centrifuged for 10 min for 2000 x g and 4˚C with break off
setting. The supernatant was transferred to new tubes without disturbing the pellet. The
plasma was stored frozen at -80˚C at the depository of Gene Bank, Yonsei University, Gang-
nam Severance Hospital, until use. Tumor tissue samples were collected during surgery.
Matched tumor tissue and plasma samples were obtained from Gene Bank. This study proto-
col was approved by the Institutional Review Board of Gangnam Severance Hospital (protocol
no: 3-2017-0008) and the requirements for informed consent was waived.
A total of 36 NSCLCs were finally selected. The clinicopathological characteristics including
the age and sex of the patients, operation type, maximal tumor diameter, tumor volume on
Fig 1. Blood sampling from lobectomy specimen. When a lobectomy specimen of fresh lung tissue was submitted to the Department
of Pathology to evaluate bronchial resection margin during surgery, peripheral blood was obtained from a pulmonary vessel.
https://doi.org/10.1371/journal.pone.0230622.g001
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chest CT, histologic subtype according to 2015 World Health Organization (WHO) classifica-
tion, lymphatic, vascular and perineural invasion, pT and pN classification, and TNM stage
were investigated. pT and pN classification and TNM stage were determined based on the 8th
edition of the American Joint Committee on Cancer staging system.
Histopathological evaluation
Cytological atypia was classified into three categories as follows: mild, relatively uniform nuclei
with indistinct nucleoli at x100 magnification; moderate, relatively uniform nuclei with dis-
tinct nucleoli at x100 magnification; severe, bizarre, enlarged nuclei of variable sizes. For het-
erogeneous tumors, the highest degree of atypia was recorded.
For mitotic rate, we examined 10 high power fields (HPFs) using an Olympus BX41 micro-
scope at x400 magnification (objective, x40; visible area, 2.37mm2) in the most mitotically
active area.
Measurement of tumor volume
Tumor volume was retrospectively measured on preoperative chest CT images. The mean
time interval between CT scan and surgery was 29 days (range, 0–105). CT scans of the chest
were performed using one of the following scanners: Somatom Sensation 16, Somatom Sensa-
tion 64, Somatom Definition AS+ (all Siemens Medical Solutions, Erlangen, Germany), or
Brilliance 64 CT (Philips Healthcare, Best, The Netherlands). In the supine position, CT
images were obtained from the lung apex to the adrenal glands at the end of inspiration. CT
parameters were as follows: 120 kVp, 50–130 mAs, and 1–3-mm scan thickness at 1–3-mm
intervals. A board-certified chest radiologist with 10 years of experience (CHP) measured
tumor volume, blinded to the pathologic results. For volumetric analysis, all axial CT images
were analyzed using a commercially available reconstruction program (Aquarius iNtuition™
Ver.4.4.6; TeraRecon, Foster City, CA, USA). Each tumor margin was manually drawn by a
radiologist on every axial CT image in the lung window setting and three dimensional tumor
area was determined by integrating all axial images. The tumor volume was calculated auto-
matically by adding the volumes of all voxels within the segmented tumor area.
Mutation analysis for tissue
Genomic DNA was extracted from 10% neutral-buffered formalin-fixed, paraffin-embedded
tumor tissue using the Maxwell 16 FFPE Plus LEV DNA Purification kit (Promega, Manheim,
Germany) according to manufacturer’s instruction. DNA was quantified using a fluorescence
assay (Invitrogen) and 10–25 ng of DNA was used for mutation analysis. The PANAmuty-
perTM R EGFR and KRAS detection kit (PANAGENE Inc., Daejeon, South Korea) was used
for mutation detection. PANAmutyperTM R is a PCR-based multiplex assay that uses peptide
nucleic acids (PNA) that complementarily bind to the wild-type DNA and suppress its amplifi-
cation. Therefore, a very small amount of mutant DNA can be selectively amplified and
detected with high sensitivity: the limit of detection is between 0.01% and 0.1% when using 2
mL of plasma. PANAmutyperTM R can be used both in plasma and tissue. PANAmutyperTM R
is an in vitro diagnostic test which qualitatively detect defined EGFR and KRAS mutations.
The equality of detecting EGFR mutation between PANAmutyperTM R EGFR and Roche
cobas1 EGFR mutation test v2 was proved. Korean Ministry of Food and Drug Safety
approved PANAmutyperTM R EGFR as a companion diagnostic test to select patients for erlo-
tinib or osimertinib. The PANAmutyperTM R EGFR kit can detect EGFR mutations, such as
G719X, exon 19 deletions, T790M, S768I, exon 20 insertion, L858R, L861Q, and C797S.
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PANAmutyperTM R KRAS kit can detect point mutations in codon 12, 13, 59, 61, 117, and 146
of the KRAS gene.
Mutation analysis for plasma
Circulating cell-free (cfDNA) was extracted from 2 mL of plasma using the QIAamp Circulat-
ing Nuclei Acid Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. The
PANAmutyperTM R EGFR and KRAS detection kit was used for mutation detection. Quantifi-
cation of ctDNA extracted from plasma was omitted. DNA extracted from tissue exists in large
amount, so suppression of wild type DNA by clamp probe is not sufficient and false positive
result would be possible. However, ctDNA exists in a very small level and adequate volume of
plasma containing ctDNA (required volume in PANAMutyper: 2mL) should be used. If the
quality or quantity of ctDNA in plasma sample is not adequate, real time PCR cannot be car-
ried out. In this study, all plasma samples were successfully amplified.
Statistical analysis
The Fisher’s exact and Mann-Whitney U tests were used for categorical and continuous vari-
ables to examine the correlation between the presence of ctDNA and each clinicopathological
parameter. A p value of<0.05 was considered statistically significant. All statistical analyses
were performed using SPSS software version 12.0 (SPSS, Chicago, IL, USA) and MedCalc ver-
sion 18.11.6. (MedCalc Software, Mariakerke, Belgium) for Windows.
Results
Clinicopathological characteristics
The baseline characteristics of the patients are summarized in Table 1. Most patients (35 out of
36) had a primary tumor and one patient had a recurrent tumor. Two patients, who had nei-
ther EGFR nor KRAS mutation in their primary lung tumors had undergone neoadjuvant che-
motherapy before surgery. All patients were naïve to TKI treatment before surgical resection
of the tumor. All cases were ALK gene rearrangement negative.
EGFR and KRAS mutations in tumor tissue and plasma
Detailed EGFR and KRAS mutation results for matched plasma and tissue samples are pre-
sented in Table 2. In 19 out 36 patients, both peripheral and specimen blood were available
and showed the same results. In 17 patients, either peripheral or specimen blood were avail-
able. EGFR and KRAS mutations in tissue was detected only in adenocarcinomas. Concurrent
mutations of T790M and L858R were present in one case, while C797S was not detected in any
cases. Among adenocarcinomas, EGFR and KRAS mutations were present in 55.6% (15/27)
and 22.2% (6/27) of tissue samples, respectively. Comparison of EGFR and KRAS mutation
status between tissue and plasma was summarized in Tables 3 and 4. The concordance rate
between tissue and plasma samples was 63.9% in EGFR and 88.9% in KRAS. Among EGFR or
KRAS- mutant tumors, the mutation detection sensitivity of the plasma sample was 13.3% (2/
15) for EGFR and 33.3% (2/6) for KRAS. The overall sensitivity of detecting driver mutation in
plasma was 19.0%. The mutation detection specificity of plasma was 100% for both EGFR (21/
21) and KRAS (30/30).
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Table 1. Baseline characteristics of non-small cell carcinoma (n = 36).
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Invasive mucinous adenocarcinoma 2
Squamous cell carcinoma 6
























�Stages adapted from the American Joint Committee on Cancer TNM staging system, 8th edition
https://doi.org/10.1371/journal.pone.0230622.t001
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EGFR and KRAS mutation detection in plasma and its clinicopathological
correlation
The presence of ctDNA in plasma was significantly associated with higher pathological tumor
stage (p = 0.008), nodal metastasis (p = 0.013), solid adenocarcinoma pattern (p = 0.002), and
Table 2. Detailed results of EGFR and KRAS mutations in matched plasma and tissue samples.
Histologic subtype Stage Case No. EGFR mutation KRAS mutation
Peripheral blood Specimen blood Tissue Peripheral blood Specimen blood Tissue
ADC I 1 n/a wt wt n/a wt wt
5 wt n/a L858R wt n/a wt
6 wt wt wt wt wt wt
8 wt wt L858R
T790M
wt wt wt
9 wt wt wt wt wt wt
10 n/a wt wt n/a wt wt
11 n/a wt L858R n/a wt wt
15 wt wt E19del wt wt wt
18 wt wt wt Wt wt G12V
22 wt wt E19del wt wt wt
24 wt n/a wt wt n/a G12A
26 wt wt L858R wt wt wt
28 wt n/a L858R wt n/a wt
29 wt n/a E19del wt n/a wt
30 wt n/a E19del wt n/a wt
32 wt n/a E19del wt n/a wt
33 wt n/a L858R wt n/a wt
36 wt wt E19del wt wt wt
II 16 n/a wt wt n/a wt wt
31� wt wt wt wt wt wt
35 L858R n/a L858R wt n/a wt
III 4 wt wt wt G12D G12D G12D
12 wt wt G719A wt wt wt
13 n/a wt wt n/a G12V G12V
14† n/a wt wt n/a wt G12D
17 n/a wt wt n/a wt wt
19 L858R L858R L858R wt wt wt
IV 34 wt n/a wt wt n/a Q61H
SqCC I 7� wt wt wt wt wt wt
21 wt wt wt wt wt wt
27 wt wt wt wt wt wt
20 wt wt wt wt wt wt
II 2 n/a wt wt n/a wt wt
25 wt wt wt wt wt wt
MEC I 3 wt wt wt wt wt wt
LCNEC III 23 wt wt wt wt wt wt
ADC, adenocarcinoma; SqCC, squamous cell carcinoma; MEC, mucoepidermoid carcinoma; LCNEC, large cell neuroendocrine carcinoma; wt, wild type; n/a, not
applicable
� cases with neoadjuvant chemotherapy
† recurred case
https://doi.org/10.1371/journal.pone.0230622.t002
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tumor necrosis (p = 0.002) in tissue specimens (Table 5). Higher TNM stage (p = 0.053), vascu-
lar invasion by tumor (p = 0.08) and severe cytological atypia (p = 0.053) were marginally asso-
ciated with ctDNA shedding. In addition, tumors shedding ctDNA in plasma had significantly
larger tumor diameter (median [Q1-Q3], 6.8 [5.2–8.6] cm vs. 2.3 [1.90–3.2] cm; p = 0.002),
tumor volume (median [Q1-Q3], 81.7 [62.3~142.2] cm3 vs. 5.5 [2.2–8.7] cm3; p = 0.002), and
higher mitotic rate (median [Q1-Q3], 12.5 [2.8–17] vs 0 [0–1]; p = 0.018) than non-shedding
tumors (Table 5). In box plots of maximal tumor diameter (Fig 2) and tumor volume (Fig 3),
all tumors larger than 4cm in maximal diameter or 25 cm3 in volume shed ctDNA in plasma,
while tumors smaller than the cutoff did not. In box plot of mitotic rate (Fig 4), tumors with
more than 6 mitoses per 10 HPFs were more likely to shed ctDNA. The presence of ctDNA in
plasma was not related to other clinicopathological feautres such as sex, pleural invasion, lym-
phatic invasion, and gross type of the tumor. Among four tumors shedding ctDNA, three
cases were solid predominant adenocarcinoma with tumor necrosis, vascular invasion, severe
cytological atypia, and lymph node metastasis (Fig 5A and 5B). One case was a 9 cm-sized
pneumonic type adenocarcinoma that did not show necrosis, lymphovascular invasion, and
node metastasis (Fig 5C and 5D).
In subgroup analysis, detection of EGFR mutated ctDNA was significantly associated with nodal
metastasis (p = 0.029), vascular invasion (p = 0.029), solid adenocarcinoma pattern (p = 0.010), and
tumor necrosis (p = 0.010) of primary tumor (Table 6). In addition, tumors shedding EGFR mutant
ctDNA in plasma had significantly larger tumor diameter (median [range], 5.45 [4.9–6.0] cm vs.
2.5 [0.8–3.5] cm; p = 0.027), tumor volume (median [range], 64.0 [44.60~83.40] cm3 vs. 5.45 [0.48–
21.80] cm3; p = 0.027), and higher mitotic rate (median [range] per 10 HPFs, 16 [14–18] vs 0 [0–5];
p = 0.009) than non-shedding tumors (Table 6). However, detection of KRAS mutated ctDNA was
not significantly associated with any clinicopathological features.
Discussion
cfDNA is the extracellular DNA present in the blood that is released from normal as wells as
tumor cells, fetuses [12], and viruses. ctDNA represents a small fraction of cfDNA, which is
Table 3. Comparison of EGFR mutation status between matched tissue and plasma samples.
Tissue EGFR mutation Subtotal
Mutant Wild type
ctDNA EGFR mutation
Mutant 2 0 2
Wild type 13 21 34
Subtotal 15 21 36
ctDNA, circulating tumor DNA
https://doi.org/10.1371/journal.pone.0230622.t003
Table 4. Comparison of KRAS mutation status between matched tissue and plasma samples.
Tissue KRAS mutation Subtotal
Mutant Wild type
ctDNA KRAS mutation
Mutant 2 0 2
Wild type 4 30 34
Subtotal 6 30 36
ctDNA, circulating tumor DNA
https://doi.org/10.1371/journal.pone.0230622.t004
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originated from tumor cells. It is considered to be shed when the phagocytic macrophages are
exhausted to scavenge ctDNA fragments produced during tumor apoptosis or necrosis [6].
Living tumor cells actively secret ctDNA via exosomes to communicate with distant tissue [7,
Table 5. Clinicopathological parameters according to the mutant ctDNA in EGFR or KRAS-mutant lung adenocarcinoma (n = 21).
Clinicopathological features Mutant ctDNA in plasma
Present (n = 4) Absent (n = 17) P Odds ratio 95% CI
Categorical variables�
Sex 1.0 1.125 0.127–9.943
Male 2 (50.0%) 9 (52.9%)
Female 2 (50.0%) 8 (47.1%)
Tumor stage 0.028 22.50 1.510–335.338
pT1, T2 1 (25.0%) 15 (88.2%)
pT3, T4 3 (75.0%) 2 (11.8%)
Nodal stage† 0.016 42.0 2.010–877.471
pN0 1 (25.0%) 14 (93.3%)
pN1, N2 3 (75.0%) 1 (6.7%)
TNM stage 0.053 14.0 1.057–185.492
Stage 1, 2 1 (25.0%) 14 (82.4%)
Stage 3, 4 3 (75.0%) 3 (17.6%)
Pleural invasion 1.0 1.083 0.087–13.538
Absent 3 (75.0%) 13 (76.5%)
Present 1 (25.0%) 4 (23.5%)
Vascular invasion 0.080 16.0 0.959–267.033
Absent 2 (50.0%) 15 (94.1%)
Present 2 (50.0%) 1 (5.9%)
Lymphatic invasion 1.0 1.556 0.117–20.610
Absent 3 (75.0%) 14 (82.4%)
Present 1 (25.0%) 3 (17.6%)
Solid predominant pattern 0.003 81.667 2.7249-
2447.567No 1 (25.0%) 17 (100%)
Yes 3 (75.0%) 0 (0%)
Tumor necrosis 0.012 48.0 2.311–997.176
Absent 1 (25.0%) 16 (94.1%)
Present 3 (75.0%) 1 (5.9%)
Cytological atypia 0.053 14.0 1.057–185.492
Mild to moderate 1 (25.0%) 14 (82.4%)
Severe 3 (75.0%) 3 (17.6%)
Gross type of the tumor 1.0 0.80 0.066–9.669
Solid 3 (75.0%) 12 (70.6%)
Subsolid 1 (25.0%) 5 (29.4%)
Continuous variables (median [Q1-Q3]) ‡
Maximal tumor diameter (cm) 6.8 (5.2–8.6) 2.3 (1.9–3.2) 0.002
Tumor volume from chest CT (cm3) 81.7 (62.3–142.2) 5.5 (2.2–8.7) 0.002
Mitotic count per 10 HPFs 12.5 (2.8–17) 0 (0–1) 0.018
� Fisher’s exact test with two-sided P values
†Lymph node dissection was performed in 19 patients.
‡ Mann-Whitney U test
https://doi.org/10.1371/journal.pone.0230622.t005
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13]. Tumor cells circulating in the blood can also contribute to release ctDNA [14]. Tumor
DNA contains unique somatic mutation, so mutant DNA in the blood is highly tumor-specific
and can be used as tumor biomarkers. Clinical test for detecting mutated tumor DNA in blood
sample (liquid biopsy) has become an important goal in NSCLC because obtaining adequate
tumor tissues for molecular analysis is not always feasible in advanced lung cancer patients.
The sensitivity of plasma EGFR mutation detection using PCR methods was recently
reported to be 10% to 22.2% in stage I-IIIA lung cancer [15, 16]. In this study, the concordance
rate between plasma obtained before surgery and resected tissue was 63.8% in EGFR and
88.9% in KRAS; sensitivity was 13.3% in EGFR and 33.3% in KRAS. This concordance and
Fig 2. Box and whisker plot of pathological tumor size in non-shedding and shedding tumors.
https://doi.org/10.1371/journal.pone.0230622.g002
Fig 3. Box and whisker plot of tumor volume measured from chest CT in non-shedding and shedding tumors.
https://doi.org/10.1371/journal.pone.0230622.g003
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sensitivity is low in our study compared to a similar study by Han et al. [17] that used an
advanced NSCLC cohort (concordance rate 82.0% for EGFR and 85.9% for KRAS; sensitivity
66.7% for EGFR and 50.0% in KRAS). The low concordance and sensitivity in our study are
likely due to false negatives on plasma analysis. Considering that both studies used the same
plasma detection flatform (PANAmutyperTM R), tumor biology might determine the sensitiv-
ity. Our study cohort included earlier tumor stages, so tumors in our study might be less likely
to release ctDNA compared to Han et al.’s cohort.
In the present study, sensitivity of ctDNA detection was higher in KRAS than EGFR. How-
ever, this is hard to generalize because the number of KRAS mutated lung adenocarcinoma is
much smaller (n = 6) than EGFR mutated adenocarcinoma (n = 15) in this study cohort. Fur-
ther study with larger sample size including more KRAS mutated tumors is needed to clarify
this.
Two studies compared ctDNA obtained before surgery and tumor tissue DNA using NGS
in surgically resected lung cancer patients [8, 18]. Since NGS can detect various mutations in
many genes, we calculated the plasma detection sensitivity of EGFR and KRAS mutations in
those studies for comparison with our results. The sensitivity of plasma EGFR mutation detec-
tion in Chen’s and Guo’s studies were 56.5% and 63.2%, respectively; the sensitivity of plasma
KRAS mutation detection was 60.0% and 50.0%. The specificity of plasma EGFR mutation
detection was 72.7% and 75.0%; the specificity for KRAS, 95.0% and 96.0%. The sensitivity for
plasma detection of EGFR and KRAS mutations in these two studies using NGS was superior
to our study, but the specificity was lower. The authors suggested that false-positive plasma
result could be attributed to intratumoral heterogeneity. However, intratumoral heterogeneity
is usually related to tumor progression, recurrence, and resistance to therapy [19]. In addition,
except for T790M and C797S mutations in EGFR, EGFR and KRAS mutations in NSCLC
occur early in carcinogenesis and intratumoral heterogeneity of both genes is rare [20, 21].
Therefore, validation with tissue samples is crucial when performing plasma genotyping, espe-
cially in treatment-naïve patients and in the initial phases of NSCLC before progression.
Fig 4. Box and whisker plot of mitotic count per 10 high power fields in non-shedding and shedding tumors.
https://doi.org/10.1371/journal.pone.0230622.g004
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There are factors affecting false negativity in ctDNA analysis. In the pre-analytical phase,
contamination with normal DNA from leukocyte lysis during blood clotting dilutes ctDNA
and leads to detection failure. Using plasma rather than serum, collecting blood in a K2 EDTA
tube, and isolating plasma within 6 hours after sampling can minimize pre-analytical error
[22]. In the analytical phase, the limit of detection of ctDNA assay is an important determinant
of sensitivity. Generally, NGS-based methods are more sensitive than PCR-based methods for
detecting low levels of DNA. However, even deep sequencing by NGS could not detect ctDNA
in 10% of cases in a recent report [23]. This implies that detection of ctDNA in plasma depends
on other factors such as ctDNA shedding. In the post-analytical phase, degree of cfDNA shed-
ding determines the sensitivity of ctDNA tests. For example, ctDNA can easily be detected in
tumors shedding ctDNA more heavily into plasma than can be cleared by the liver and kidney.
In advanced NSCLC, ctDNA detection is related to tumor burden as well as extrathoracic
lymph node and bone metastasis [24]. In early-stage NSCLC, Abbosh et al. showed that non-
adenocarcinoma histology, lymphovascular invasion, and high Ki-67 proliferation index were
Fig 5. Representative cases with ctDNA shedding in plasma. A-B, A solid predominant adenocarcinoma with EGFR
L858R mutation in both tissue and plasma (case no. 35). The tumor showed vascular invasion (A, ×40), necrosis (B; left
side of the picture, ×200), cytological atypia, and frequent mitosis (B, arrow heads). C-D, A pneumonic-type
adenocarcinoma with KRAS G12V mutation in both tissue and plasma (case no. 13). Large tumor in the right lower
lobe on chest CT image is delineated by arrow heads (C). The tumor showed adenocarcinoma with mixed papillary
and lepidic pattern (D, ×40).
https://doi.org/10.1371/journal.pone.0230622.g005
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independent predictors of ctDNA detection [9]. Chen et al. reported that higher stage (stage II
rather than I) and GGO-dominant status led to a significantly higher cfDNA level [8].
In this study, ctDNA shedding in surgically resected adenocarcinoma was related to higher
pathological T stage, nodal metastasis, solid adenocarcinoma pattern, tumor necrosis, high
Table 6. Subgroup analysis of clinicopathological parameters according to the mutant ctDNA in EGFR-mutant lung adenocarcinoma (n = 15).
Clinicopathological features Mutant EGFR ctDNA in plasma
Present (n = 2) Absent (n = 13) P Odds ratio 95% CI
Categorical variables�
Sex 0.467 1.333 0.894–1.989
Male 0 (0%) 7 (53.8%)
Female 2 (100%) 6 (46.2%)
Tumor stage 0.133 0.071 0.011–0.472
pT1, T2 1 (50.0%) 13 (100%)
pT3, T4 1 (50.0%) 0 (0%)
Nodal stage† 0.029 3.0 0.606–14.864
pN0 0 (0%) 12 (92.3%)
pN1, N2 2 (100%) 1 (7.7%)
TNM stage 0.257 12.0 0.384–374.837
Stage 1, 2 1 (50%) 12 (92.3%)
Stage 3, 4 1 (50%) 1 (7.7%)
Pleural invasion 0.371 5.50 0.235–128.968
Absent 1 (50%) 11 (84.6%)
Present 1 (50%) 2 (15.4%)
Vascular invasion 0.029 3.0 0.606–14.864
Absent 0 (0%) 12 (92.3%)
Present 2 (100%) 1 (7.7%)
Lymphatic invasion 0.371 5.5 0.235–128.968
Absent 1 (50%) 11 (84.6%)
Present 1 (50%) 2 (15.4%)
Solid predominant pattern 0.010 Not applicable
No 0 (0%) 13 (100%)
Yes 2 (100%) 0 (0%)
Tumor necrosis 0.010 Not applicable
Absent 0 (0%) 13 (100%)
Present 2 (100%) 0 (0%)
Cytological atypia 0.057 2.0 0.751–5.329
Mild to moderate 0 (0%) 11 (82.6%)
Severe 2 (100%) 2 (15.4%)
Gross type of the tumor 0.524 0.80 0.587–1.091
Solid 2 (100%) 8 (61.5%)
Subsolid 0 (0%) 5 (38.5%)
Continuous variables (median [range]) †
Maximal tumor diameter (cm) 5.45 (4.9–6.0) 2.5 (0.8–3.5) 0.027
Tumor volume from chest CT (cm3) 64.0 (44.60–83.40) 5.45 (0.48–21.80) 0.027
Mitotic count per 10 HPFs 16 (14–18) 0 (0–5) 0.009
� Fisher’s exact test with two-sided P values
† Mann-Whitney U test
https://doi.org/10.1371/journal.pone.0230622.t006
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mitotic rate, large pathological tumor size, and large tumor volume on CT. In subgroup analy-
sis among EGFR mutated adenocarcinoma, ctDNA was significantly associated with nodal
metastasis, vascular invasion, solid adenocarcinoma pattern, and tumor necrosis, high mitotic
rate, large pathological tumor size, and large tumor volume on CT. However, KRAS mutated
ctDNA was not significantly associated with any clinicopathological features, probably due to
small number of KRAS mutated tumor. On case reviews, all three cases of solid predominant
adenocarcinoma released ctDNA into plasma and most showed tumor necrosis, vascular inva-
sion, frequent mitosis, severe cytological atypia, and nodal metastasis. However, one case with
a large primary tumor size and volume also released ctDNA, despite the absence of other
aggressive features. Thus, primary tumor size and volume are an important predictor of
ctDNA shedding. Abbosh et al. also showed that tumor burden was correlated with mean
plasma variant allele frequency [9]. In the present study, all tumors larger than 4 cm in maxi-
mal diameter or 25 cm3 in volume shed enough ctDNA in plasma to be detected using a PCR-
based method with a 0.1% of limit of detection.
This study has some limitations. First, the sample size of this study is quite small, so we
could not perform in-depth analysis. Collecting sufficient preoperative blood samples from
each NSCLC patient is difficult at a single institute. Further studies with a larger sample size
are needed to define pathophysiology of ctDNA shedding. Second, the ctDNA detection
method of our study (PNA clamping-assisted PCR) is less sensitive and less informative than
NGS-based methods. However, PCR-based plasma testing is cost-effective, fast, and simple to
interpret in daily practice, and thus we believe these findings have more practical value in the
real world setting.
In summary, this study evaluated EGFR and KRAS mutations in matched tissue and preop-
erative plasma samples from surgically resected NSCLC and assessed the clinicopathological
predictors for ctDNA release in plasma. Shedding of ctDNA from tumor tissue into plasma is
low (overall sensitivity 19.0%) in surgically resected NSCLC patients. Our results suggested
that primary tumor size and volume as well as aggressive histologic features such as solid ade-
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